Switzerland
· Delayed Price · Currency is CHF Kuros Biosciences AG Company Description
Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development for tissue repair and bone regeneration in the United States, the European Union, and internationally.
It operates through three segments: Medical Devices, Pharmaceuticals, and Legacy Portfolio. The company offers MagnetOs Granules, an original advanced bone graft based on the submicron needle-shaped NeedleGrip surface technology; MagnetOs Putty, a mold use to fill bony voids for a predictable fusion; MagnetOs Easypack Putty, a ready-to-use mold to be implanted in any intervertebral disc space or posterolateral spine level; and Magnetos Flex Matrix, an open matrix bone graft.
Its Fibrin-PTH pipeline products comprise KUR-111 and KUR-113 that are in Phase 2b clinical trials for trauma indications; KUR-113 that is in Phase 2a clinical trial for spinal indications.
The company was incorporated in 2016 and is headquartered in Schlieren, Switzerland.
| Country | Switzerland |
| Founded | 2016 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 106 |
| CEO | Christopher Fair |
Contact Details
Address: Wagistrasse 25 Schlieren, 8952 Switzerland | |
| Phone | 41 44 733 4747 |
| Website | kuros.ch |
Stock Details
| Ticker Symbol | KURN |
| Exchange | SIX Swiss Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CHF |
| ISIN Number | CH0325814116 |
| SIC Code | 2836 |